Document is current
Any future updates will be listed below
-
Authors
Unterman, Avraham https://orcid.org/0000-0003-0965-3326
Sumida, Tomokazu S. https://orcid.org/0000-0002-9806-2642
Nouri, Nima https://orcid.org/0000-0001-8348-5717
Yan, Xiting
Zhao, Amy Y.
Gasque, Victor https://orcid.org/0000-0001-7505-305X
Schupp, Jonas C. https://orcid.org/0000-0002-7714-8076
Asashima, Hiromitsu
Liu, Yunqing
Cosme, Carlos Jr.
Deng, Wenxuan
Chen, Ming
Raredon, Micha Sam Brickman https://orcid.org/0000-0003-1441-6122
Hoehn, Kenneth B. https://orcid.org/0000-0003-0411-4307
Wang, Guilin
Wang, Zuoheng https://orcid.org/0000-0002-7251-3687
DeIuliis, Giuseppe https://orcid.org/0000-0003-0841-8156
Ravindra, Neal G. https://orcid.org/0000-0001-5558-3758
Li, Ningshan
Castaldi, Christopher
Wong, Patrick
Fournier, John
Bermejo, Santos
Sharma, Lokesh https://orcid.org/0000-0003-3040-9029
Casanovas-Massana, Arnau https://orcid.org/0000-0002-3301-6143
Vogels, Chantal B. F. https://orcid.org/0000-0003-0027-6480
Wyllie, Anne L. https://orcid.org/0000-0001-6015-0279
Grubaugh, Nathan D.
Melillo, Anthony
Meng, Hailong
Stein, Yan https://orcid.org/0000-0003-0335-5897
Minasyan, Maksym
Mohanty, Subhasis
Ruff, William E. https://orcid.org/0000-0001-5828-6425
Cohen, Inessa
Raddassi, Khadir
,
Nelson, Allison
Shepard, Denise
Rainone, Michael
Peng, Xiaohua
Niklason, Laura E.
Ko, Albert I. https://orcid.org/0000-0001-9023-2339
Montgomery, Ruth R. https://orcid.org/0000-0002-8661-4454
Farhadian, Shelli F. https://orcid.org/0000-0001-7230-1409
Iwasaki, Akiko https://orcid.org/0000-0002-7824-9856
Shaw, Albert C.
van Dijk, David https://orcid.org/0000-0003-3911-9925
Zhao, Hongyu https://orcid.org/0000-0003-1195-9607
Kleinstein, Steven H. https://orcid.org/0000-0003-4957-1544
Hafler, David A. https://orcid.org/0000-0003-4664-535X
Kaminski, Naftali https://orcid.org/0000-0001-5917-4601
Dela Cruz, Charles S. https://orcid.org/0000-0002-5258-1797
-
Funding
Funding for this research was provided by:
Department of Internal Medicine at Yale School of Medicine
- License Information
-
More Information
Article History
Received: 28 July 2020
Accepted: 3 December 2021
First Online: 21 January 2022
Competing interests
: S.H.K. receives consulting fees from Northrop Grumman. L.E.N. is a founder and shareholder in Humacyte, Inc, which is a regenerative medicine company. Humacyte produces engineered blood vessels from allogeneic smooth muscle cells for vascular surgery. L.E.N.’s spouse has equity in Humacyte, and L.E.N. serves on Humacyte’s Board of Directors. L.E.N. is an inventor on patents that are licensed to Humacyte and that produce royalties for L.E.N. L.E.N. has received an unrestricted research gift to support research in her laboratory at Yale. Humacyte did not fund these studies, and Humacyte did not influence the conduct, description, or interpretation of the findings in this report. N.D.G. is a paid consultant for Tempus Labs and the National Basketball Association. A.I.K. received consulting fees from Tata Sons and Regeneron and is a recipient of grants on COVID-19 from Merck, Regeneron, and Serimmune all of which are outside the submitted work. K.B.H. receives consulting fees from Prellis Biologics. C.D.C. is a recipient of a grant from BMS. A.U. reports personal consulting fees from Boehringer Ingelheim, RemedyCell, Augmanity Nano, and 1E Therapeutics in the last 36 months, and Equity in RemedyCell, all outside the submitted work. D.A.H. has received research funding from Bristol-Myers Squibb, Novartis, Sanofi, and Genentech. He has been a consultant for Bayer Pharmaceuticals, Bristol Myers Squibb, Compass Therapeutics, EMD Serono, Genentech, Juno Therapeutics, Novartis Pharmaceuticals, Proclara Biosciences, Sage Therapeutics, and Sanofi Genzyme. Further information regarding funding is available on: . N.K. reports personal fees from Boehringer Ingelheim, Third Rock, Pliant, Samumed, NuMedii, Indalo, Theravance, LifeMax, Three Lake Partners, RohBar, Astra Zeneca, Veracyte, Augmanity, CSL Behring, and Thyron in the last 36 months, and reports equity in Pliant and Thyron. N.K. is also a recipient of a grant from Veracyte Boehringer Ingelheim, BMS, and non-financial support from MiRagen and Astra Zeneca. All outside the submitted work; in addition, N.K. has patents on New Therapies in Pulmonary Fibrosis and ARDS (optioned to biotech) and Peripheral Blood Gene Expression as biomarkers in IPF (licensed to biotech). T.S.S., N.N., X.Y., A.Y.Z., V.G., J.C.S., H.A., Y.L., C.C.Jr., W.D., M.C., M.S.B.R., G.W., Z.W., G.D., N.G.R., N.L., C.C., P.W., J.F., S.B., L.S., A.C., C.B.F.V., A.L.W., A.M., H.M., Y.S., M.M., S.M., W.E.R, I.C., K.R., R.R.M., S.F.F., A.I., A.C.S., D.V.D., and H.Z. declare no competing interests.
